- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Venture capitalists back device firm incubator
Menlo Park, CA?Three venture capital firms have promised $2.4 million in seed funding to start ForSight Labs, a new incubator of firms to launch ophthalmic medical device technologies. Representatives of Morgenthaler Ventures, Split Rock Partners, and Versant Ventures will also take seats on the ForSight Labs board of directors.
Menlo Park, CA-Three venture capital firms have promised $2.4 million in seed funding to start ForSight Labs, a new incubator of firms to launch ophthalmic medical device technologies. Representatives of Morgenthaler Ventures, Split Rock Partners, and Versant Ventures will also take seats on the ForSight Labs board of directors.
The incubator is led by renowned inventor and ophthalmology professor Eugene de Juan, MD, and The Foundry, an incubator responsible for developing nine medical device companies, most of which focus on cardiovascular therapies.
ForSight aims to build companies with ophthalmic products for glaucoma, cataracts, and age-related macular degeneration, as well as drug-delivery technology.
